Research work · 2020

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Suzanne Lopez

The Lancet Oncology

Read free full text

DOI: 10.1016/s1470-2045(20)30445-9